JAGUAR HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.18 USD | +5.88% |
|
+14.72% | +18.89% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 145,236 | 7,275 | 4,089 | 213.4 | 26.27 | 7.684 |
| Enterprise Value (EV) 1 | 145,249 | 7,279 | 4,097 | 225.7 | 55.63 | 38.31 |
| P/E ratio | - | -0.09 x | -0.81 x | -0.88 x | -0.18 x | -0.08 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 32,887 x | 1,260 x | 436 x | 49.2 x | 2.2 x | 0.79 x |
| EV / Revenue | 32,891 x | 1,260 x | 437 x | 52.1 x | 4.65 x | 3.92 x |
| EV / EBITDA | -5,979 x | -325 x | -209 x | -6.04 x | -1.72 x | -1.2 x |
| EV / FCF | -9,812 x | -651 x | -464 x | -12.7 x | -3.37 x | -2.23 x |
| FCF Yield | -0.01% | -0.15% | -0.22% | -7.88% | -29.6% | -44.8% |
| Price to Book | 26,980 x | 812 x | 28 x | 18.6 x | -42.7 x | 2.24 x |
| Nbr of stocks (in thousands) | 40,303 | 40,368 | 22,297 | 2,735 | 4,030 | 50,756 |
| Reference price 2 | 3,604 | 180.2 | 183.4 | 78.00 | 6.518 | 0.1514 |
| Announcement Date | 4/10/19 | 4/3/20 | 3/31/21 | 3/11/22 | 3/24/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.416 | 5.775 | 9.385 | 4.335 | 11.96 | 9.761 |
| EBITDA 1 | -24.29 | -22.37 | -19.58 | -37.36 | -32.43 | -31.91 |
| EBIT 1 | -25.61 | -24.11 | -21.3 | -39.07 | -34.42 | -33.92 |
| Operating Margin | -579.99% | -417.39% | -227% | -901.36% | -287.85% | -347.51% |
| Earnings before Tax (EBT) 1 | -32.15 | -38.53 | -33.81 | -52.6 | -48.4 | -41.9 |
| Net income 1 | -32.15 | -38.54 | -33.81 | -52.6 | -47.45 | -41.3 |
| Net margin | -727.92% | -667.32% | -360.25% | -1,213.38% | -396.91% | -423.11% |
| EPS | - | -2,027 | -225.0 | -88.23 | -36.18 | -1.790 |
| Free Cash Flow 1 | -14.8 | -11.18 | -8.83 | -17.78 | -16.49 | -17.15 |
| FCF margin | -335.22% | -193.5% | -94.09% | -410.18% | -137.91% | -175.75% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/10/19 | 4/3/20 | 3/31/21 | 3/11/22 | 3/24/23 | 4/1/24 |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.63 | 2.08 | 2.625 | 2.921 | 3.15 | 3.26 | - | 2.676 | 2.813 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -9.529 | -10.82 | -11.75 | -6.479 | -9.896 | -6.286 | - | -8.102 | -8.787 |
| Operating Margin | -1,512.54% | -520.29% | -447.77% | -221.81% | -314.16% | -192.82% | - | -302.77% | -312.37% |
| Earnings before Tax (EBT) 1 | -12.19 | -14.32 | -18.16 | -9.39 | -12.61 | -8.232 | - | -12.29 | -7.904 |
| Net income 1 | -12.19 | -14.31 | -17.99 | -9.367 | -12.52 | -7.581 | -12.2 | -12.15 | -7.778 |
| Net margin | -1,935.24% | -688.12% | -685.18% | -320.68% | -397.46% | -232.55% | - | -454.04% | -276.5% |
| EPS 2 | -20.25 | -23.25 | -30.00 | -9.000 | -9.000 | - | -2.390 | -0.6900 | -0.3800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/17/21 | 3/11/22 | 5/10/22 | 8/22/22 | 11/14/22 | 3/24/23 | 5/15/23 | 8/14/23 | 11/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 13.5 | 4.07 | 8.12 | 12.3 | 29.4 | 30.6 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.5564 x | -0.1819 x | -0.4148 x | -0.3296 x | -0.9054 x | -0.9598 x |
| Free Cash Flow 1 | -14.8 | -11.2 | -8.83 | -17.8 | -16.5 | -17.2 |
| ROE (net income / shareholders' equity) | -203% | -221% | -179% | -362% | -922% | -2,367% |
| ROA (Net income/ Total Assets) | -37.8% | -38.9% | -33.6% | -50.8% | -42.7% | -43.2% |
| Assets 1 | 85.01 | 99.06 | 100.6 | 103.5 | 111.1 | 95.67 |
| Book Value Per Share 2 | 0.1300 | 0.2200 | 6.550 | 4.200 | -0.1500 | 0.0700 |
| Cash Flow per Share 2 | 0.0600 | 0.0900 | 3.080 | 6.170 | 1.270 | 0.0900 |
| Capex 1 | 0.01 | - | 0.01 | 0.01 | 0.08 | - |
| Capex / Sales | 0.15% | - | 0.07% | 0.14% | 0.64% | - |
| Announcement Date | 4/10/19 | 4/3/20 | 3/31/21 | 3/11/22 | 3/24/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +18.89% | 49.72M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- JAGX Stock
- Financials Jaguar Health, Inc.
